Transvaginal Mesh for pelvic organ prolapse in Taiwan (2004–2025): Outcomes and safety in the wake of the 2019 FDA licensing halt
Document Type
Article
Publication Date
5-1-2026
Abstract
Objective: To review the evolution, outcomes and safety of transvaginal mesh (TVM) use for pelvic organ prolapse (POP) repair in Taiwan from January 2004 to May 2025. Materials and methods: A systematic literature search in PubMed using MeSH terms “transvaginal mesh” AND “Pelvic organ prolapse”, yielding 856 articles. Of these 96 Taiwanese studies were included, comprising 10 prospective trials, 1 meta-analysis, and the remainder retrospective studies. A total of 88 study cases involving various mesh types were analyzed. Results: Objective cure rates exceeded 90% at 1-year across most mesh types, with significant improvements in quality of life measured by validated questionnaires (POPDI-6, IIQ-7, UDI-6, PISQ-12). Mesh extrusion rates with newer generation meshes (2019–2023) ranged from 0.8% to 4.8%. Most complications, such as urinary tract infections and voiding dysfunction, were minor and manageable. Surelift, Calistar-S and MIPS, the only currently approved meshes for transvaginal use in Asia, showed promising one-year cure rates, all exceeding 92%. Surelift demonstrated superiority more than native tissue repair at 5 years, with success rates of 89.1% vs. 64.4% (p = 0.002). Older age was associated with increased risk of voiding dysfunction and recurrence (HR 1.07, if > 64 years). Obesity did not increase mesh-related complications but has greater postoperative symptom burden. Concomitant MUS effectively reduced de novo stress urinary incontinence from 31.2% to 5%. Conclusion: TVM continues to be a reliable and effective option for POP management. Taiwan's experience highlights the importance of proper training, patient selection, and surgical refinement in minimizing complications. Long-term follow-up and awareness of red-flag symptoms remains essential.
Keywords
Pelvic organ prolapse, Sacrospinous mesh, Single incision mesh, Trans-obturator mesh, Transvaginal mesh
Publication Title
Taiwanese Journal of Obstetrics and Gynecology
ISSN
1028-4559
DOI
10.1016/j.tjog.2025.10.009
Recommended Citation
Lo, Tsia Shu; Kamarudina, Maherah; Rellora, Louiza Erika; Yang, Chia Hsuan; Hsieh, Wu Chiao; and Lin, Yi Hao, "Transvaginal Mesh for pelvic organ prolapse in Taiwan (2004–2025): Outcomes and safety in the wake of the 2019 FDA licensing halt" (2026). Research Publications (2026 to 2030). 689.
https://knova.um.edu.my/research_publications_2026_2030/689
Volume
65
Issue
3
First Page
465
Last Page
488